Brokerages Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $13.86

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been assigned an average recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.8571.

A number of research analysts recently issued reports on the company. Needham & Company LLC dropped their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Citigroup reissued a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Finally, Jefferies Financial Group restated a “buy” rating and set a $12.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, April 30th.

Insiders Place Their Bets

In related news, CEO Kevin Lee sold 5,905 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total transaction of $25,214.35. Following the completion of the sale, the chief executive officer owned 605,408 shares in the company, valued at $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 9,977 shares of company stock worth $42,702. 22.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fcpm Iii Services B.V. boosted its stake in shares of Bicycle Therapeutics by 0.5% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after buying an additional 16,100 shares during the period. Armistice Capital LLC increased its position in Bicycle Therapeutics by 8.7% in the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after acquiring an additional 258,000 shares during the period. Westfield Capital Management Co. LP raised its stake in Bicycle Therapeutics by 2.2% during the 4th quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock valued at $21,353,000 after acquiring an additional 63,483 shares during the last quarter. GSK plc purchased a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $10,829,000. Finally, Principal Financial Group Inc. lifted its position in Bicycle Therapeutics by 2.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock worth $5,450,000 after acquiring an additional 26,353 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $3.90 on Friday. The company has a fifty day moving average of $4.10 and a two-hundred day moving average of $4.74. The company has a market capitalization of $272.26 million, a PE ratio of -1.43 and a beta of 1.55. Bicycle Therapeutics has a 1 year low of $3.74 and a 1 year high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $4.22 million. On average, research analysts expect that Bicycle Therapeutics will post -2.23 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.